Patents Examined by Robert A. Zeman
-
Patent number: 8187610Abstract: The invention provides Streptococcus vaccine strains (e.g. S. equi which is causative of ‘strangles’) comprising the following modifications in their genomes: (i) attenuation of one or more essential biosynthetic genes, (ii) attenuation of one or more genes which encode a haemolytic toxin, or protein involved in the production thereof, plus preferably any one, two, or most preferably three of the following modifications: (iii) attenuation of one or more genes which encode a protein responsible for immune evasion (iv) modification of one or more genes such as to permit serological discrimination of the vaccine strain based on analysis of a protein encoded by said genes, and (v) attenuation of one or more genes which encode an enzyme responsible for recombination repair of the genome. The invention provides inter alia live attenuated vaccine strains which generate an immune response to multiple protective epitopes presented in a context resembling the live pathogen.Type: GrantFiled: January 20, 2009Date of Patent: May 29, 2012Assignee: Animal Health TrustInventors: Andrew Stephen Waller, Carl Robinson, Zoe Heather
-
Patent number: 8178339Abstract: Reduced genome strains of E. coli MG1655 are described. In various embodiments, the strains have one or more of equal or improved growth rate, transformation efficiency, protein expression, DNA production, DNA yield and/or DNA quality compared to the parental strain and commercially available strains.Type: GrantFiled: August 18, 2006Date of Patent: May 15, 2012Assignee: Scarab Genomics LLCInventors: John W Campbell, Frederick R. Blattner, Guy Plunkett, Gyorgy Posfai
-
Patent number: 8153138Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.Type: GrantFiled: September 19, 2006Date of Patent: April 10, 2012Assignee: GSF-Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Gerd Sutter, Marion Ohlmann, Volker Erfle
-
Patent number: 8153132Abstract: Antibodies immunoreactive to mutant Pseudomonas HPPD are provided, and in an embodiment the mutant HPPD is one in which the wild-type HPPD is substituted at residue 336 with tryptophan for glycine. Also provided are hybridomas producing the antibodies, as well as methods of making and using the antibodies.Type: GrantFiled: October 30, 2009Date of Patent: April 10, 2012Assignee: MS Technologies, Inc.Inventors: Vaithilingam Sekar, Bruce Held, Kyu Chung, Paul F. Russell, Jr.
-
Patent number: 8147822Abstract: The present invention is directed to a method of reducing the viability of a tumor cell involving administering a virus that is not a common human pathogen to the tumor cell. Preferably, the virus exhibits differential susceptibility, in that normal cells are not affected by the virus. This differential susceptibility is more pronounced in the presence of interferon. The tumor cell is characterized by having low levels, or no, PKR activity, or as being PKR?/?, STAT1?/? or both PKR?/? and STAT1?/?. The virus is selected from the group consisting of Rhabdovirus and picornavirus, and preferably is vesicular stomatitis virus (VSV) or a derivative thereof.Type: GrantFiled: September 18, 2000Date of Patent: April 3, 2012Assignee: Wellstat Biologics CorporationInventors: John C. Bell, Nahum Sonenberg, David F. Stojdl, Earl G. Brown, Harold L. Atkins, Ricardo M. Marius, Brian D. Lichty, Shane B. Knowles
-
Patent number: 8114666Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.Type: GrantFiled: July 19, 2011Date of Patent: February 14, 2012Assignee: Boehringer Ingelheim Vetmedica GmbHInventor: Malik Merza
-
Patent number: 8114667Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.Type: GrantFiled: July 19, 2011Date of Patent: February 14, 2012Assignee: Boehringer Ingelheim Vetmedica GmbHInventor: Malik Merza
-
Patent number: 8106155Abstract: A test kit for detecting an antibiotic or antibiotics containing a ?-lactam ring in a biological fluid is provided. The test kit includes at least one recognition agent, which is a receptor which specifically binds to antibiotics containing a ?-lactam ring and is obtained from Bacillus licheniformis. The test kit further contains at least one reference antibiotic immobilized on a solid support.Type: GrantFiled: June 14, 2002Date of Patent: January 31, 2012Assignee: Neogen CorporationInventors: Jacques Degelaen, Benoît Granier, Jean-Marie Frere, Bernard Joris
-
Patent number: 8097717Abstract: This invention relates to a composition comprising a chaotropic agent, a buffering substance, and 0.5 to 5% (V/V) polidocanol or a derivative thereof. The invention is further related to uses of this composition and to a kit comprising the composition according to the invention. The invention is further related to a method for the detection of a nucleic acid in a biological sample comprising the steps of incubating the biological sample in the presence of a chaotropic agent, a buffering substance, and 0.5 to 5% (V/V) polidocanol or a derivative thereof, optionally isolating the nucleic acid, optionally amplifying the nucleic acid, and detecting the nucleic acid. The invention is further related to a method for the purification of a nucleic acid in a biological sample comprising the steps of incubating the biological sample in the presence of a chaotropic agent, a buffering substance, and 0.5 to 5% (V/V) polidocanol or a derivative thereof and isolating the nucleic acid thereby purifying the nucleic acid.Type: GrantFiled: August 24, 2011Date of Patent: January 17, 2012Assignee: Roche Molecular Systems, Inc.Inventors: Sigrid Adie, Hermann Leying, Nicole Nachbaur, Eberhard Russmann
-
Patent number: 8093034Abstract: This invention relates to the optimization of culture conditions to improve the production of bacterial capsular polysaccharides from Streptococcus strains in fed-batch culture.Type: GrantFiled: November 1, 2006Date of Patent: January 10, 2012Assignee: Novartis AGInventor: Erwin Frans Swennen
-
Patent number: 8058062Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.Type: GrantFiled: July 19, 2011Date of Patent: November 15, 2011Assignee: Boehringer Ingelheim Vetmedica GmbHInventor: Malik Merza
-
Patent number: 8026049Abstract: The invention is methods and related kits for diagnosing a disease state of cachexia by measuring biomarker profiles from a biological sample. Rapid measurement of early onset or progression of the disease in a subject is determined by measuring biomarker levels from the subject and optionally comparing the biomarker levels to a standard biomarker profile or metabolome phase portrait for the disease. The biomarkers measured in the assay and related kit for cachexia progression include biomarkers selected from the group consisting of lactate, citrate, formate, acetoacetate, 3-hydroxy butrate, alanine, glutamine, glutamate, valine, isoleucine leucine, thrionine, lysine, arginine, tyrosine, phenyl alanine, histidine and tryptophan.Type: GrantFiled: March 24, 2008Date of Patent: September 27, 2011Assignee: Wisconsin Alumni Research FoundationInventors: Fariba Masoumeh Assadi-Porter, Mark E. Cook, Hamid Reza Eghbalnia, Marco Tonelli, Warren Paul Porter, Daniel Elmer Butz
-
Patent number: 8021667Abstract: The present invention relates to an immunogenic composition comprising a conjugate between an antigen and an oxidized mannan comprising mannose units and aldehyde groups, and a pharmaceutically acceptable carrier.Type: GrantFiled: November 17, 2006Date of Patent: September 20, 2011Assignee: MacFarlane Burnet Institute for Medical Research and Public Health LtdInventors: Ian F. C. McKenzie, Vasso Apostolopoulos, Geoffrey A. Pietersz
-
Patent number: 8021663Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.Type: GrantFiled: April 28, 2011Date of Patent: September 20, 2011Assignee: Boehringer Ingelheim Vetmedica GmbHInventor: Malik Merza
-
Patent number: 8007802Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.Type: GrantFiled: April 28, 2011Date of Patent: August 30, 2011Assignee: Boehringer Ingelheim Vetmedica GmbHInventor: Malik Merza
-
Patent number: 8007801Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.Type: GrantFiled: April 28, 2011Date of Patent: August 30, 2011Assignee: Boehringer Ingelheim Vetmedica GmbHInventor: Malik Merza
-
Patent number: 8003107Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.Type: GrantFiled: April 28, 2011Date of Patent: August 23, 2011Assignee: Boehringer Ingelheim Vetmedica GmbHInventor: Malik Merza
-
Patent number: 7998668Abstract: A method for determining whether a human individual is or has been infected with Neisseria gonorrhoeae, is provided. The method detects a Neisseria gonorrhoeae, porA nucleic acid fragment obtained from a biological sample. The method includes subjecting the biological sample to nucleic acid sequence amplification using primers having respective nucleotide sequences according to SEQ ID NO:1 and SEQ ID NO:2, to thereby produce a porA Neisseria gonorrhoeae, amplification product. The amplification product is detected by fluorescence resonance energy transfer using oligonucleotides having respective nucleotide sequences according to SEQ ID NO:3 which has a donor fluorophore and SEQ ID NO:4, which has an acceptor fluorophore.Type: GrantFiled: April 6, 2005Date of Patent: August 16, 2011Assignee: The State of Queensland Acting Through Its Department of HealthInventors: David Mark Whiley, Theo Pieter Sloots
-
Patent number: 7993649Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.Type: GrantFiled: April 28, 2011Date of Patent: August 9, 2011Assignee: Boehringer Ingelheim Vetmedica GmbHInventor: Malik Merza
-
Patent number: 7988977Abstract: Safe and effective live vaccines against Aeromonas hydrophila of fish were created through the induction of rifampicin resistance in native Aeromonas hydrophila isolates; these including rifampicin-resistant mutants NRRL-B-50040 and NRRL-B-50041. Single immersion exposure of fish stimulated acquired immunity against virulent Aeromonas hydrophila infection.Type: GrantFiled: February 27, 2009Date of Patent: August 2, 2011Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Phillip H. Klesius, Craig A. Shoemaker, Joyce L. Evans